Replies to post #347771 on Anavex Life Sciences Corp (AVXL)

[mike_dotcom]

I hope the market figures it out before we hit $7. It's looking like an ugly day today - so far.

[vg_future]

end2war, it is intentional misleading by few...not mis-understanding. These crooks are specifically led/fed by AF. I hope someone takes criminal action against this guy.

-vg_future

[oldandintheway]

"Muted?" I think the word you meant was "catastrophic."

[LBSR TO DA MOON]

Judging by the early response, it probably would have been helpful to include this type of information in this morning's PR...

Muted response of PPS to these extremely positive results is due to a misunderstanding about the reasons for the change of the endpoint measurements. Missling explained that, for this PH3 study, this approached to the endpoints was based on FDA advice about what would be required, and it was prespecified for this study. According to Missling, they met a much more difficult endpoint standard with this required approach, and it was comparable or better than in the prior reported Study.

[tredenwater2]

If someone on twitter is spreading false information regarding our results Dr. Missling needs to use a portion of our warchest and blow up this guys world with a team of lawyers. This is ridiculous but then again, there is no cabal so it all must be a fair and balanced market, right?

I know, maybe Dr. Missling should take a page out of Sava’s playbook and re release the data in a week! Lol

[attilathehunt]

“, and it was comparable or better than in the prior reported Study. “

Which is it? If prior study he should know if it was comparable or better. He should be more exact (especially since he is German). He didn’t appear to at the top of the game.

I believe we will see approval before end of year 2022. Opportunity to buy I guess.

[falconer66a]

Anavex MOA WORKS. PDD and Alzheimer's Next!

When the market figures it out, I believe the PPS will reflect the excellent progress, and how much this supports AVXL's other studies using the S1R receptors.

The results announced today are really fine for girls suffering from Rett syndrome. Now, they have some hope for a more normalized life.

But there's a much bigger factor, for the millions suffering from Parkinson's disease and Alzheimer's disease. For both of those recalcitrant central nervous system (CNS) diseases the unique, particular mechanism of action (MOA) of blarcamesine, binding to and propitiously activating the sigma-1 receptor protein, was still in question. Sure, pre-clinical studies in diseased murines (lab rodents), along with some early safety and tolerability (Phase 1) studies in humans strongly indicated that blarcamesine would be both safe and therapeutic, but both the MOA and the therapeutic results were still in question in humans.

Understandably. All of the murine results from blarcamesine were "too good to be true." No obviating side effects --- extremely uncommon in neuroactive drugs. Then, results too good to be true. Transgenic rats with severe, fully-developed human-genetic Alzheimer's get their cognition rather fully restored. Of course, that was by a similar Anavex drug, Anavex 3-71. But it's MOA is identical to blarcamesine's; acting on the sigma-1 receptor protein.

It is now fully established that in humans the blarcamesine MOA is therapeutically functional. It WORKS. Because of that, the results in the on-going Phase 3 Parkinson's disease dementia and Alzheimer's disease trials will be positive. Medical science will be changed going forward. Sigma-1 receptor protein activation will be quickly entered in the med-school textbooks. In the 1940s it was penicillin and antibiotics. In the 2020s it will be the Anavex drugs and their CNS therapeutics.